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Research on the implications of anxiety in Parkinson’s disease (PD) has been neglected despite its prevalence in nearly 50% of
patients and its negative impact on quality of life. Previous reports have noted that neuropsychiatric symptoms impair cognitive
performance in PD patients; however, to date, no study has directly compared PD patients with and without anxiety to examine
the impact of anxiety on cognitive impairments in PD.This study compared cognitive performance across 50 PD participants with
and without anxiety (17 PDA+; 33 PDA−), who underwent neurological and neuropsychological assessment. Group performance
was compared across the following cognitive domains: simple attention/visuomotor processing speed, executive function (e.g., set-
shifting), working memory, language, and memory/new verbal learning. Results showed that PDA+ performed significantly worse
on the Digit Span forward and backward test and Part B of the Trail Making Task (TMT-B) compared to the PDA− group. There
were no group differences in verbal fluency, logical memory, or TMT-A performance. In conclusion, anxiety in PD has ameasurable
impact on working memory and attentional set-shifting.
1. Introduction
Anxiety affects quality of life in those living with Parkinson’s
disease (PD) more so than overall cognitive status, motor
deficits, apathy, and depression [1–3]. Although anxiety and
depression are often related and coexist in PD patients [4],
recent research suggests that anxiety rather than depression
is themost prominent and prevalent mood disorder in PD [5,
6]. Yet, our current understanding of anxiety and its impact
on cognition in PD, as well as its neural basis and best treat-
ment practices, remains meager and lags far behind that of
depression [7].
Overall, neuropsychiatric symptoms in PD have been
shown to be negatively associated with cognitive perfor-
mance. For example, higher depression scores have been
correlated with lower scores on the Mini-Mental State Exam
(MMSE) [8, 9] as well as tests of memory and executive func-
tions (e.g., attention) [10–14]. Likewise, apathy and anhedonia
in PD patients have been associated with executive dysfunc-
tion [10, 15–23]. However, few studies have specifically inves-
tigated the relationship between anxiety and cognition in PD.
One study showed a strong negative relationship between
anxiety (both state and trait) and overall cognitive perfor-
mance (measured by the total of the repeatable battery for
the assessment of neuropsychological status index) within
a sample of 27 PD patients [24]. Furthermore, trait anxiety
was negatively associated with each of the cognitive domains
assessed by the RBANS (i.e., immediatememory, visuospatial
construction, language, attention, and delayedmemory). Two
further studies have examined whether anxiety differentially
affects cognition in patients with left-sided dominant PD
(LPD) versus right-sided dominant PD (RPD); however,
their findings were inconsistent. The first study found that
working memory performance was worse in LPD patients
with anxiety compared to RPD patients with anxiety [25],
whereas the second study reported that, in LPD, apathy but
not anxiety was associated with performance on nonverbally
mediated executive functions and visuospatial tasks (e.g.,
TMT-B,WMS-III spatial span), while in RPD, anxiety but not
apathy significantly correlated with performance on verbally
mediated tasks (e.g., clock reading test and Boston naming
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Table 1: Demographic and clinical variables in PD participants.
Variable PDA−(𝑁 = 33)
PDA+
(𝑁 = 17) 𝑝 values
Demographic
Age (years) 68.3 (8.9) 64.9 (8.1) 𝑝 = 0.20
Gender (% male) 19/14 (57.6%) 9/8 (52.9%) 𝑝 = 0.75
Clinical
Disease duration
(years) 6.6 (4.2) 6.6 (5.6) 𝑝 = 0.66
UPDRS-III 31.9 (13.0) 31.2 (15.3) 𝑝 = 0.65
LPD/RPD ratio
(% LPD) 15/17 (45.5%) 6/11 (35.3%) 𝑝 = 0.38
H&Y stage,
median (range) 2.0 (1–4) 2.0 (1–5) 𝑝 = 0.43
LEDD, mg/day 674.0 (550.5) 710.2 (478.7) 𝑝 = 0.80
HADS-A 2.03 (1.6) 10.5 (1.9) ∗𝑝 < 0.001
HADS-D 3.2 (1.7) 4.1 (1.6) 𝑝 = 0.06
HADS-total 5.2 (2.7) 14.7 (2.9) ∗𝑝 < 0.001
Note: values reflect mean (SD). LEDD: levodopa equivalent daily dose. ∗
indicates significant group differences.
test) [15]. Furthermore, anxiety was significantly correlated
with neuropsychological measures of attention and executive
and visuospatial functions [15]. Taken together, it is evident
that there are limited and inconsistent findings describing the
relationship between anxiety and cognition in PD and more
specifically how anxiety might influence particular domains
of cognition such as attention and memory and executive
functioning. It is also striking that, to date, no study has
examined the influence of anxiety on cognition in PD by
directly comparing groups of PD patients with and without
anxiety while excluding depression. This was the primary
objective of the current study.
Given that research on healthy young adults suggests that
anxiety reduces processing capacity and impairs processing
efficiency, especially in the central executive and attentional
systems of working memory [26, 27], we hypothesized
that PD patients with anxiety would show impairments in
attentional set-shifting and working memory compared to
PD patients without anxiety. Furthermore, since previous
work, albeit limited, has focused on the influence of symptom
laterality on anxiety and cognition, we also explored this
relationship.
2. Methods
Seventeen PD patients with anxiety and thirty-three PD
patients without anxiety were included in this study (see
Table 1). The cross-sectional data from these participants was
taken from a patient database that has been compiled over the
past 8 years (since 2008) at the Parkinson’s Disease Research
Clinic at the Brain and Mind Centre, University of Sydney.
Inclusion criteria involved a diagnosis of idiopathic PD
according to theUnitedKingdomParkinson’sDisease Society
Brain Bank criteria [28] and were confirmed by a neurologist
(SJGL). Patients also had to have an adequate proficiency
in English and have completed a full neuropsychological
assessment. Ten patients in this study (5 PD with anxiety;
5 PD without anxiety) were taking psychotropic drugs (i.e.,
benzodiazepine or selective serotonin reuptake inhibitor).
Patients with an MMSE of less than 24 were excluded.
Patients were also excluded if they had other neurological
disorders, psychiatric disorders other than affective disorders
(such as anxiety), or if they reported a score greater than
six on the depression subscale of the Hospital Anxiety and
Depression Scale (HADS). Thus, all participants who scored
within a “depressed” (HADS-D > 6) range were excluded
from this study, in attempt to examine a refined sample of
PD patients with and without anxiety in order to determine
the independent effect of anxiety on cognition. This research
was approved by the Human Research Ethics Committee of
the University of Sydney, and written informed consent was
obtained from all participants.
Self-reported HADS was used to assess anxiety in PD
and has been previously shown to be a useful measure of
clinical anxiety in PD [29].A cut-off score of>8 on the anxiety
subscale of the HADS (HADS-A) was used to identify PD
cases with anxiety (PDA+), while a cut-off score of <6 on
the HADS-A was used to identify PD cases without anxiety
(PDA−).This criterionwasmore stringent thanusual (>7 cut-
off score) [30], in effort to create distinct patient groups.
All participants underwent a neurological assessment
conducted while on their medications. The neurological
evaluation rated participants according to Hoehn and Yahr
(H&Y) stages [31] and assessed their motor symptoms using
part III of the revised MDS Task Force Unified Parkinson’s
Disease Rating Scale (UPDRS) [32]. In a similar way, symp-
tom laterality was determined by taking a left/right ratio.This
was determined by calculating a total left and right score
from rigidity items 30–35, voluntary movement items 36–43,
and tremor items 50–57 from the MDS-UPDRS part III (see
Table 1).
Neuropsychological functioning was assessed using stan-
dardized tests and appropriate normative data. A detailed
description of the neuropsychological battery was reported
elsewhere [33]. Processing speed was assessed using the Trail
Making Test, Part A (TMT-A, z-score) [34]. Attentional set-
shifting was measured using the Trail Making Test, Part
B (TMT-B, z-score) [34]. Working memory was assessed
using the Digit Span forward and backward subtest of the
Wechsler Memory Scale-III (raw scores) [35]. Language was
assessed with semantic and phonemic verbal fluency via the
Controlled Oral Word Associated test (COWAT animals and
letters, z-score) [36]. The ability to retain learned verbal
memory was assessed using the Logical Memory subtest
from the Wechsler Memory Scale-III (LM-I z-score, LM-II
z-score, % LM retention z-score) [35].TheMini-Mental State
Examination (MMSE) was used to assess global cognition.
2.1. Statistical Analyses. TheShapiro-Wilk test was performed
to determine normal distribution.Demographic, clinical, and
neuropsychological variables were compared between the
two groups with the independent t-test or Mann–Whitney
𝑈 test, depending on whether the variable met parametric
assumptions. Chi-square tests were used to examine gender
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(𝑁 = 17) 𝑝 values
Global cognition
MMSE 28.2 (1.5) 27.5 (1.8) 𝑝 = 0.23
Attention/visuomotor
processing speed
TMT-A, 𝑧-score −0.15 (1.2) 0.66 (2.23) 𝑝 = 0.62
Executive function
TMT-B, 𝑧-score −0.02 (1.1) −0.85 (1.8) ∗𝑝 = 0.048
Working memory
Digit Span forward total 10.6 (2.3) 8.8 (3.2) ∗𝑝 = 0.031
Digit Span backward total 7.2 (2.8) 5.7 (1.5) ∗𝑝 = 0.012
Language
Semantic verbal fluency,
𝑧-score −0.04 (1.0) −0.26 (1.1) 𝑝 = 0.49
Phonemic verbal fluency,




𝑧-score −0.21 (1.1) −0.83 (1.1) 𝑝 = 0.059
LM-II, 𝑧-score 0.10 (1.1) −0.29 (1.1) 𝑝 = 0.20
% LM retention, 𝑧-score 0.40 (1.2) 0.14 (1.2) 𝑝 = 0.43
Note: values represent mean (SD). ∗ indicates significant differences at the
𝑝 < 0.05 level.
and symptom laterality differences between groups. All anal-
yses employed an alpha level of 𝑝 < 0.05 and were two-
tailed. Spearman correlations were performed separately in
each group to examine associations between anxiety and/or
depression ratings and cognitive functions.
3. Results
3.1. Demographic and Clinical Characteristics. As expected,
the PDA+ group reported significant greater levels of anxiety
on the HADS-A (𝑈 = 0, 𝑝 < 0.001) and higher total score
on the HADS (𝑈 = 1, 𝑝 < 0.001) compared to the PDA−
group (Table 1). Groups were matched in age (𝑡(48) = 1.31,
𝑝 = 0.20), disease duration (𝑈 = 259, 𝑝 = 0.66), UPDRS-
III score (𝑈 = 250.5, 𝑝 = 0.65), H&Y (𝑈 = 245, 𝑝 = 0.43),
LEDD (𝑈 = 159.5, 𝑝 = 0.80), and depression (HADS-D)
(𝑈 = 190.5, 𝑝 = 0.06). Additionally, all groups were matched
in the distribution of gender (𝜒2 = 0.098, 𝑝 = 0.75) and side-
affected (𝜒2 = 0.765, 𝑝 = 0.38).
3.2. Cognitive Functioning. There were no group differences
for TMT-A performance (𝑈 = 256, 𝑝 = 0.62) (Table 2); how-
ever, the PDA+ group had worse performance on the Trail
Making Test Part B (𝑡(46) = 2.03, 𝑝 = 0.048) compared to the
PDA− group (Figure 1). The PDA+ group also demonstrated
significantly worse performance on the Digit Span forward
subtest (𝑡(48) = 2.22, 𝑝 = 0.031) and backward subtest (𝑈 =




















Figure 1: PD patients with anxiety performed significantly worse on
Part B of the Trail Making Task compared to PD patients without
anxiety. ∗ denotes 𝑝 values < 0.05. Error bars represent standard
error.
and 2(b)). Neither semantic verbal fluency (𝑡(47) = 0.70, 𝑝 =
0.49) nor phonemic verbal fluency (𝑡(47) = 0.39, 𝑝 = 0.70)
differed between groups. Logical Memory I immediate recall
test (𝑈 = 176, 𝑝 = 0.059) showed a trend that the PDA+
group had worse new verbal learning and immediate recall
abilities than the PDA− group. However, Logical Memory II
test performance (𝑈 = 219, 𝑝 = 0.204) and Logical Memory
% retention (𝑈 = 242.5, 𝑝 = 0.434) did not differ between
groups. There were also no differences between groups in
global cognition (MMSE) (𝑈 = 222.5, 𝑝 = 0.23).
3.3. Comparison within LPD and RPD Patients. Partici-
pants were split into LPD and RPD, and then further
group differences were examined between PDA+ and PDA−.
Importantly, the groups remained matched in age, disease
duration, UPDRS-III, DDE, H&Y stage, and depression
but remained significantly different on self-reported anxiety.
LPDA+ demonstrated worse performance on the Digit Span
forward test (𝑡(19) = 2.29, 𝑝 = 0.033) compared to LPDA−,
whereas RPDA+ demonstrated worse performance on the
Digit Span backward test (𝑈 = 36.5, 𝑝 = 0.006), LM-I
immediate recall (𝑈 = 37.5,𝑝 = 0.008), and LM-II (𝑈 = 45.0,
𝑝 = 0.021) but not LM % retention (𝑈 = 75.5, 𝑝 = 0.39)
compared to RPDA−.
4. Discussion
This study is the first to directly compare cognition between
PDpatients with andwithout anxiety.Thefindings confirmed
our hypothesis that anxiety negatively influences attentional
set-shifting andworkingmemory in PD.More specifically, we
found that PD patients with anxiety were more impaired on
the Trail Making Test Part B which assessed attentional set-
shifting, on both Digit Span Tests which assessed working
memory and attention, and to a lesser extent on the Log-
ical Memory test which assessed memory and new verbal
learning compared to PD patients without anxiety. Taken
together, these findings suggest that anxiety in PD may
reduce processing capacity and impair processing efficiency,
especially in the central executive and attentional systems of
working memory in a similar way as seen in young healthy
adults [26, 27].








































Figure 2: PD patients with anxiety performed significantly worse on the Digit Span forward (a) and backward (b) test compared to PD
patients without anxiety. ∗ denotes 𝑝 values < 0.05. Error bars represent standard error of the means.
Although the neurobiology of anxiety in PD remains
unknown, many researchers have postulated that anxiety
disorders are related to neurochemical changes that occur
during the early, premotor stages of PD-related degeneration
[37, 38] such as nigrostriatal dopamine depletion, as well
as cell loss within serotonergic and noradrenergic brainstem
nuclei (i.e., raphe nuclei and locus coeruleus, resp., which
provide massive inputs to corticolimbic regions). Over time,
chronic dysregulation of adrenocortical and catecholamine
functions can lead to hippocampal damage as well as dys-
functional prefrontal neural circuitries [39, 40], which play
a key role in memory and attention [24]. Recent functional
neuroimaging work has suggested that enhanced hippocam-
pal activation during executive functioning and working
memory tasks may represent compensatory processes for
impaired frontostriatal functions in PD patients compared
to controls [41]. Therefore, chronic stress from anxiety, for
example, may disrupt compensatory processes in PD patients
and explain the cognitive impairments specifically inworking
memory and attention seen in PD patients with anxiety. It has
also been suggested that hyperactivation within the putamen
may reflect a compensatory striatal mechanism to maintain
normal working memory performance in PD patients; how-
ever, losing this compensatory activation has been shown
to contribute to poor working memory performance [42].
Anxiety in mild PD has been linked to reduced putamen
dopamine uptake which becomes more extensive as the
disease progresses [43]. This further supports the notion that
anxiety may disrupt compensatory striatal mechanisms as
well, providing another possible explanation for the cognitive
impairments observed in PD patients with anxiety in this
study.
Noradrenergic and serotonergic systems should also be
considered when trying to explain the mechanisms by which
anxiety may influence cognition in PD. Although these neu-
rotransmitter systems are relatively understudied in PD cog-
nition, treating the noradrenergic and serotonergic systems
has shown beneficial effects on cognition in PD. Selective
serotonin reuptake inhibitor, Citalopram, was shown to
improve response inhibition deficits in PD [44], while nora-
drenaline reuptake blocker, atomoxetine, has been recently
reported to have promising effects on cognition in PD [45,
46].
Overall, very few neuroimaging studies have been con-
ducted in PD in order to understand the neural correlates
of PD anxiety and its underlying neural pathology. Future
research should focus on relating anatomical changes and
neurochemical changes to neural activation in order to gain
a clearer understanding on how these pathologies affect
anxiety in PD. To further understand how anxiety and
cognitive dysfunction are related, future research should
focus on using advanced structural and function imaging
techniques to explain both cognitive and neural breakdowns
that are associated with anxiety in PD patients. Research has
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indicated that those with amnestic mild cognitive impair-
ment who have more neuropsychiatric symptoms have a
greater risk of developing dementia compared to those with
fewer neuropsychiatric symptoms [10]. Future studies should
also examine whether treating neuropsychiatric symptoms
might impact the progression of cognitive decline and
improve cognitive impairments in PD patients.
4.1. Does Symptom Laterality Influence the Effect of Anxiety
on Cognition? Previous studies have used PD symptom
laterality as a window to infer asymmetrical dysfunction
of neural circuits. For example, LPD patients have greater
inferred right hemisphere pathology, whereas RPD patients
have greater inferred left hemisphere pathology [15]. Thus,
cognitive domains predominantly subserved by the left hemi-
sphere (e.g., verballymediated tasks of executive function and
verbal memory) might be hypothesized to be more affected
in RPD than LPD; however, this remains controversial [47].
It has also been suggested that since anxiety is a common
feature of left hemisphere involvement [48, 49], cognitive
domains subserved by the left hemisphere may also be more
strongly related to anxiety [15]. Results from this study
showed selective verbal memory deficits in RPD patients
with anxiety compared to RPD without anxiety, whereas
LPD patients with anxiety had greater attentional/working
memory deficits compared to LPDwithout anxiety. Although
these results align with previous research [15], interpretations
of these findings should bemadewith caution due to the small
sample size in the LPD comparison specifically.
4.2. Limitations, Considerations, and Future Directions. We
would like to acknowledge a few shortcomings of this study.
Recent work has suggested that the HADS questionnaire may
underestimate the burden of anxiety related symptomology
and therefore be a less sensitive measure of anxiety in PD
[30, 50]. In addition, our small sample size also limited the
statistical power for detecting significant findings. Based on
these limitations, our findings are likely conservative and
underrepresent the true impact anxiety has on cognition in
PD. Additionally, the current study employed a very brief
neuropsychological assessment including one or two tests
for each cognitive domain. Future studies are encouraged to
collect a more complex and comprehensive battery from a
larger sample of PDparticipants in order to better understand
the role anxiety plays on cognition in PD.
Another limitation of this study was the absence of
diagnostic interviews to characterize participants’ psychiatric
symptoms and specify the type of anxiety disorders included
in this study. Future studies should perform diagnostic
interviews with participants (e.g., using DSM-V criteria)
rather than relying on self-reported measures to group par-
ticipants, in order to better understand whether the type of
anxiety disorder (e.g., social anxiety, phobias, panic disorders,
and generalized anxiety) influences cognitive performance
differently in PD.
One advantage the HADS questionnaire provided over
other anxiety scales was that it assessed both anxiety and
depression simultaneously and allowed us to control for
coexisting depression. Although there was a trend that the
PDA+ group self-reported higher levels of depression than
the PDA− group, all participants included in the study scored
<6 on the depression subscale of the HADS. Controlling for
depressionwhile assessing anxiety has been identified as a key
shortcoming in the majority of recent work [10]. Considering
many previous studies have investigated the influence of
depression on cognition in PD without accounting for the
presence of anxiety and the inconsistent findings reported
to date, we recommend that future research should try to
disentangle the influence of anxiety versus depression on
cognitive impairments in PD.
Considering the growing number of clinical trials for
treating depression, there are few if any for the treatment of
anxiety in PD. Anxiety is a key contributor to decreased qual-
ity of life in PD and greatly requires better treatment options.
Moreover, anxiety has been suggested to play a key role in
freezing of gait (FOG) [51], which is also related to atten-
tional set-shifting [52, 53]. Future research should examine
the link between anxiety, set-shifting, and FOG, in order
to determine whether treating anxiety might be a potential
therapy for improving FOG.
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